PTC Therapeutics Stock
PTC Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Matthew Klein
- Employees
- 991
- Market cap
- $4.9 B
- IPO
- 20/06/2013
PTC Therapeutics, Inc. is a healthcare company based in Warren, US, dedicated to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. The company's robust pipeline encompasses both commercialized therapies and a variety of experimental drug…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
PTC Therapeutics stock: price history
1D
-2.9%
1W
-8.4%
1M
-12.4%
6M
-18.2%
YTD
-22.0%
1Y
-11.3%
2Y
+61.4%
5Y
+55.5%
10Y
+684.6%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~2% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about PTC Therapeutics
Analyst assessment of PTC Therapeutics
PRICE TARGET LOW
US$75.00
CONSENSUS
US$102.50
MEDIAN
US$101.00
PRICE TARGET HIGH
US$137.00
0
STRONG BUY
17
BUY
7
HOLD
2
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 08/10/2026
PTC Therapeutics stock metrics
P/E
-120.9
P/B
-29.74
EV/EBITDA
26.46
RETURN ON EQUITY
-50.5%
NET MARGIN
23.2%
DEBT/EQUITY
-4.21
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.3%
FLOAT SHARES
73,689,211
AVG. DAILY VOLUME (30D)
1,213,423
Insider transactions (SEC)
SCHMERTZLER MICHAEL
SCHMERTZLER MICHAEL
Boulding Mark Elliott
Boulding Mark Elliott
SCHMERTZLER MICHAEL
Institutional holders
Comparable stocks
Frequently asked questions about PTC Therapeutics stock
What does PTC Therapeutics do?
PTC Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Matthew Klein, the company employs around 991 people.
The IPO was on 20/06/2013; the stock trades on NASDAQ under the ticker PTCT.
What do analysts say about PTC Therapeutics stock?
26 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$102.50, ranging from US$75.00 to US$137.00, with a median of US$101.00.
This is an external assessment, not a statement by Market Jury.
When does PTC Therapeutics report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly -2% stronger than usual.
Does PTC Therapeutics pay a dividend?
No, PTC Therapeutics currently does not pay a dividend.
Which stocks are comparable to PTC Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get PTC Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess PTC Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.